Selecta Biosciences Announces Third Quarter 2017 Financial Results and Provides Corporate Update
07. November 2017 07:30 ET
|
Selecta Biosciences, Inc.
Patient Data From Ongoing Phase 2 Trial to be Presented Today at the American College of Rheumatology (ACR) 2017 Annual MeetingPreparations for Phase 3 Program UnderwayReceived $7.5 Million From Spark...
Selecta Biosciences Announces Upcoming Clinical and Scientific Presentations
05. Oktober 2017 08:00 ET
|
Selecta Biosciences
WATERTOWN, Mass., Oct. 05, 2017 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies...